Literature DB >> 6206939

Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary.

T Hayakawa, A Kameya, R Mizuno, A Noda, T Kondo, N Hirabayashi.   

Abstract

A case of a 49-year-old housewife with persistent hyperamylasemia, intractable amylase-rich ascites, and papillary serous cystadenocarcinoma of the ovaries is presented. The hyperamylasemia was attributable to neoplastic production of salivary-type isoamylase by analysis of isoamylase in the serum, urine, ascites, primary tumor of the ovaries and metastatic tumor of the lymph nodes. Cellular localization of amylase in the tumor tissues was demonstrated immunohistochemically in the primary and metastatic tumors using an indirect immunoperoxidase method.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206939     DOI: 10.1002/1097-0142(19841015)54:8<1662::aid-cncr2820540829>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Aberrant pancreas is not susceptible to alcoholic pancreatitis.

Authors:  T Kondo; T Hayakawa; T Shibata; M Kitagawa; Y Sakai; H Sobajima; Y Nimura; S Kondo; T Yokoi
Journal:  Int J Pancreatol       Date:  1991-04

2.  Amylase in human lungs and the female genital tract. Histochemical and immunohistochemical localization.

Authors:  Y Hayashi; M Fukayama; M Koike; T Nakayama
Journal:  Histochemistry       Date:  1986

3.  Massive haematemesis--presenting symptoms of cystadenocarcinoma of the pancreas.

Authors:  Y Baruch; Y Levy; D Goldsher; M Munichor; S Eidelman
Journal:  Postgrad Med J       Date:  1989-01       Impact factor: 2.401

4.  Amylase mRNA transcripts in normal tissues and neoplasms: the implication of different expressions of amylase isogenes.

Authors:  K Seyama; T Nukiwa; K Takahashi; H Takahashi; S Kira
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

5.  Paraneoplastic syndromes in patients with ovarian neoplasia.

Authors:  C N Hudson; M Curling; P Potsides; D G Lowe
Journal:  J R Soc Med       Date:  1993-04       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.